Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used to treat solid tumors. The company operates globally with subsidiaries in Europe, Asia, and the Americas. As of September 30, 2009, 180 CyberKnife systems were installed at customer sites (178 sold, 2 under shared ownership).
Key Financial Metrics
| Metric (in thousands) | Q3 2009 | Q3 2008 |
|---|---|---|
| Total Net Revenue | $50,575 | $55,857 |
| Gross Profit | $21,619 | $28,429 |
| Gross Margin | 42.7% | 50.9% |
| Operating Loss | $(3,622) | $(4,238) |
| Net Loss | $(3,276) | $(3,179) |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.06) |
| Cash and Cash Equivalents | $33,340 | $27,196 |
| Total Assets | $257,629 | $274,386 |
| Backlog (Refined Criteria) | $290.5 million | N/A |
Liquidity: The company reported $33.3 million in cash and cash equivalents. It maintains a secured line of credit with UBS allowing borrowings up to 75% of the par value of its Auction-Rate Securities (ARS), though no borrowings were outstanding as of September 30, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Total net revenue decreased by $5.3 million (9.5%) compared to Q3 2008. Product revenue dropped $7.1 million, while service revenue increased $3.7 million due to growth in the installed base.
- Margin Compression: Gross margin decreased from 50.9% to 42.7%. Management attributed this to a higher mix of service revenue (which has higher costs relative to product revenue), changes in sales configurations, and lower average selling prices.
- Expense Reductions: Operating expenses decreased significantly due to a workforce alignment plan executed in fiscal 2009.
- Selling and marketing expenses fell $4.8 million (35.8%).
- Research and development expenses fell $1.1 million (12.5%).
- General and administrative expenses fell $1.5 million (14.4%).
- Inventory Write-downs: The company recorded a $2.1 million loss on the write-down of inventories, reflecting excess and obsolete inventory reserves.
- Investment Activity: Net cash provided by investing activities turned positive ($2.7 million) compared to a use of $10.3 million in the prior year, driven by net sales of marketable securities.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary:
- Backlog: The company refined its backlog definition for fiscal 2010. Under the new criteria, backlog was $290.5 million as of September 30, 2009.
- Platinum Plan Recognition: Revenue recognition from legacy "Platinum" service plans (which required deferred revenue until upgrade obligations were met) contributed $10.2 million to Q3 2009 revenue. All upgrade obligations for these units were satisfied as of the period end.
- Outlook: Management believes current cash resources are sufficient to meet needs for at least the next 12 months. However, the long sales cycle (up to 24 months) means current investments may not yield revenue immediately.
Risks and Contingencies:
- Legal Proceedings: Three consolidated securities class action lawsuits were filed in July and August 2009 alleging false or misleading statements. A shareholder derivative suit and a trade secret lawsuit by Best Medical International were also filed. No liabilities have been recorded as damages are not estimable.
- Reimbursement Risk: Medicare reimbursement rates for 2009 were approximately 3% and 10% lower than 2008 rates. Future healthcare reform legislation could further reduce reimbursements.
- Economic Environment: Tightening credit markets have delayed customer financing and facility construction, leading to potential order cancellations or postponements.
- Investment Liquidity: The company holds $22.4 million in Auction-Rate Securities (ARS) that have failed to auction. These are valued at $21.2 million. The company has a "Rights Agreement" with UBS to sell these at par value between June 2010 and July 2012.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of revenue growth excluding the one-time recognition of deferred revenue from legacy Platinum plans ($10.2 million in Q3 2009).
- Inventory Health: Assess the adequacy of the $2.1 million inventory write-down and future reserve requirements given the economic slowdown.
- Backlog Conversion: Monitor the conversion rate of the $290.5 million backlog into recognized revenue, considering the risk of order cancellations due to financing delays.
- Legal Exposure: Track the status of the securities class action and trade secret lawsuits for potential future liability accruals.
- Investment Liquidity: Confirm the status of the ARS liquidity and the terms of the UBS Rights Agreement, as these assets represent a significant portion of the investment portfolio.